Abcam, ab259886, Anti-GRIK1+GRIK2 antibody [EPR23995-85]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal GluK1 antibody. Suitable for WB, ICC/IF, IHC-P and reacts with Recombinant fragment - Mouse, Mouse, Rat, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23995-85,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:WB, ICC/IF, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GRIK1 and GRIK2 also known as GluK1 and GluK2 are subunits of kainate receptors. These receptors are ionotropic glutamate receptors that facilitate excitatory neurotransmission in the central nervous system. GRIK1 and GRIK2 proteins have a molecular mass of approximately 100 kDa. They are expressed not only in the brain but also in other tissues though their expression is most abundantly observed in the hippocampus and cerebellum. These proteins play a role in modulating synaptic transmission and plasticity contributing to the overall functioning of neural circuits.
Biological function summary
Kainate receptors which include GRIK1 and GRIK2 form ion channels upon ligand binding allowing the flow of cations such as sodium and calcium across the cell membrane. These interactions significantly influence synaptic strength and neuronal communication. GRIK1 and GRIK2 often assemble in a tetrameric complex which may also include other subunits like GRIK3 enhancing the diversity of receptor functions. The activity of these receptors has a profound impact on neurodevelopment and cognitive processes.
Pathways
GRIK1 and GRIK2 play a pivotal role in glutamatergic signaling pathways specifically impacting synaptic plasticity and long-term potentiation (LTP). These pathways are critical for learning and memory formation. The kainate receptor functions alongside AMPA and NMDA receptors key participants in synaptic transmission. The collaborative interactions among these receptor types facilitate complex neuronal network activities. This involvement positions GRIK1 and GRIK2 as essential players in mediating excitatory neurotransmission that influences higher cognitive functions.
Dysregulation of GRIK1 and GRIK2 is linked with several neurological conditions including epilepsy and schizophrenia. Altered expression or function of kainate receptors can lead to imbalances in excitatory and inhibitory signaling contributing to epileptic seizures. In schizophrenia abnormalities in glutamate receptor signaling including that of GRIK1 and GRIK2 may affect cognition and perception. Additionally their interaction with proteins like NMDA receptor subunits further highlights their role in neuropsychiatric disorders. Understanding these connections can aid in the development of targeted therapeutic approaches.